196 related articles for article (PubMed ID: 29523572)
1. Prognostic significance of autoantibodies for idiopathic pulmonary fibrosis: protocol for a systematic review.
Kamiya H; Panlaqui OM
BMJ Open; 2018 Mar; 8(3):e020862. PubMed ID: 29523572
[TBL] [Abstract][Full Text] [Related]
2. Systematic review and meta-analysis of clinical significance of autoantibodies for idiopathic pulmonary fibrosis.
Kamiya H; Panlaqui OM
BMJ Open; 2019 May; 9(5):e027849. PubMed ID: 31147365
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for acute exacerbation of idiopathic pulmonary fibrosis: protocol for a systematic review and meta-analysis.
Kamiya H; Panlaqui OM
BMJ Open; 2019 May; 9(5):e028226. PubMed ID: 31129597
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of idiopathic inflammatory myopathies complicated with interstitial lung disease: protocol for a systematic review and meta-analysis.
Kamiya H; Panlaqui OM; Izumi S; Sozu T
BMJ Open; 2016 Nov; 6(11):e012744. PubMed ID: 27856478
[TBL] [Abstract][Full Text] [Related]
5. Effect of home-based pulmonary rehabilitation on functional capacity in people with idiopathic pulmonary fibrosis-a systematic review protocol.
Amin R; Vaishali K; Maiya GA; Mohapatra AK; Yadav UN; Parsekar SS
Syst Rev; 2021 Nov; 10(1):297. PubMed ID: 34782011
[TBL] [Abstract][Full Text] [Related]
6. Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year.
Collins BF; Spiekerman CF; Shaw MA; Ho LA; Hayes J; Spada CA; Stamato CM; Raghu G
Chest; 2017 Jul; 152(1):103-112. PubMed ID: 28300570
[TBL] [Abstract][Full Text] [Related]
7. Systematic review and meta-analysis of the prognosis and prognostic factors of interstitial pneumonia with autoimmune features.
Kamiya H; Panlaqui OM
BMJ Open; 2019 Dec; 9(12):e031444. PubMed ID: 31831537
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis.
Ghang B; Lee J; Chan Kwon O; Ahn SM; Oh JS; Hong S; Kim YG; Yoo B; Jeong WS; Kim J; Lee CK
Respir Med; 2019 Aug; 155():43-48. PubMed ID: 31299466
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis: a scoping review protocol.
Bramhill C; Langan D; Mulryan H; Eustace-Cook J; Russell AM; Brady AM
BMJ Open; 2023 May; 13(5):e070513. PubMed ID: 37130693
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Fidler L; Sitzer N; Shapera S; Shah PS
Chest; 2018 Jun; 153(6):1405-1415. PubMed ID: 29559309
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review.
Fois AG; Paliogiannis P; Sotgia S; Mangoni AA; Zinellu E; Pirina P; Carru C; Zinellu A
Respir Res; 2018 Mar; 19(1):51. PubMed ID: 29587761
[TBL] [Abstract][Full Text] [Related]
12. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of prognostic factors of acute exacerbation of idiopathic pulmonary fibrosis.
Kamiya H; Panlaqui OM
BMJ Open; 2020 Jun; 10(6):e035420. PubMed ID: 32540889
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of recombinant human soluble thrombomodulin (rhsTM) treatment for acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
Kamiya H; Panlaqui OM
BMC Pulm Med; 2020 Mar; 20(1):57. PubMed ID: 32122329
[TBL] [Abstract][Full Text] [Related]
15. High serum concentrations of autoantibodies to HSP47 in nonspecific interstitial pneumonia compared with idiopathic pulmonary fibrosis.
Kakugawa T; Yokota S; Mukae H; Kubota H; Sakamoto N; Mizunoe S; Matsuoka Y; Kadota J; Fujii N; Nagata K; Kohno S
BMC Pulm Med; 2008 Nov; 8():23. PubMed ID: 18983650
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Qiu M; Chen Y; Ye Q
Clin Respir J; 2018 Mar; 12(3):1084-1092. PubMed ID: 28332341
[TBL] [Abstract][Full Text] [Related]
17. Risk of progression of idiopathic pulmonary fibrosis to connective tissue disease: a long-term observational study in 527 patients.
Ghang B; Nam SH; Lee J; Lim DH; Ahn SM; Oh JS; Hong S; Kim YG; Yoo B; Kim J; Lee CK
Clin Rheumatol; 2021 Jun; 40(6):2447-2456. PubMed ID: 33754221
[TBL] [Abstract][Full Text] [Related]
18. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
19. Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.
Donahoe M; Valentine VG; Chien N; Gibson KF; Raval JS; Saul M; Xue J; Zhang Y; Duncan SR
PLoS One; 2015; 10(6):e0127771. PubMed ID: 26083430
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of tissue factor in patients with pancreatic cancer: a systematic review protocol.
Li H; Yu Y; Shi Q; Chen X; Zheng P; Wang D; Tao P; Gu B; Li X; Zhang T; Xiang L; Xi D; Gao L; Maswikiti Ewetse P; Chen H
BMJ Open; 2020 Sep; 10(9):e037431. PubMed ID: 32928856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
